ANCA-associated vasculitides: Pathogenetic aspects and current evidence-based therapy

被引：11

作者：

Holle, J. U. ^{[1
]}

Gross, W. L.

机构：

[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, D-23538 Lubeck, Germany

来源：

JOURNAL OF AUTOIMMUNITY | 2009年 / 32卷 / 3-4期

关键词：

ANCA-associated vasculitis; Wegener's granulomatosis; Evidence-based therapy; EULAR recommendations; CHURG-STRAUSS-SYNDROME; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; REFRACTORY WEGENERS-GRANULOMATOSIS; ANTIBODY-ASSOCIATED VASCULITIS; TNF-ALPHA BLOCKADE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TERM-FOLLOW-UP; RANDOMIZED-TRIAL; MYCOPHENOLATE-MOFETIL; POLYARTERITIS-NODOSA;

D O I：

10.1016/j.jaut.2009.02.019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A lot of progress has been made regarding the therapy of ANCA-associated vasculitides in the past decades. Cyclophosphamide still is standard therapy for remission induction in generalized disease, however, duration and cumulative dose of cyclophosphamide have been curtailed successfully to reduce toxicity. MTX is a safe alternative for remission induction in early systemic disease and medications available for remission maintenance have been extended. Rituximab and TNFalpha-antagonists represent promising options for refractory disease. The current evidence of therapy of ANCA-associated vasculitides is summarized in this review. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：163 / 171

页数：9

共 50 条

[1] Treatment of ANCA-associated vasculitides (AAV)
Holle, Julia U.
Gross, Wolfgang L.
AUTOIMMUNITY REVIEWS, 2013, 12 (04) : 483 - 486
[2] New aspects in ANCA-associated vasculitides
Lamprecht, P
MEDIZINISCHE KLINIK, 2004, 99 (09) : 518 - 522
[3] De-escalation of therapy in ANCA-associated vasculitides
Schinke, S.
Riemekasten, G.
Lamprecht, P.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2017, 76 (01): : 15 - 20
[4] ANCA-Associated Vasculitides: Diagnosis and Therapy in Emergency Situations
Hellmich, B.
Gause, A.
AKTUELLE RHEUMATOLOGIE, 2010, 35 (01) : 33 - 42
[5] New therapeutic approaches for ANCA-associated vasculitides
Chaigne, Benjamin
Guillevin, Loic
PRESSE MEDICALE, 2016, 45 (06): : E171 - E178
[6] ANCA-associated vasculitides: advances in pathophysiology and treatment
Erwig, L-P.
Savage, C. O. S.
NETHERLANDS JOURNAL OF MEDICINE, 2010, 68 (02): : 62 - 67
[7] Treatment strategies for ANCA-associated vasculitides
Hellmich, B.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (05): : 388 - 397
[8] Treatment of renal ANCA-associated vasculitides
Rowaiye, Olumide Olatubosun
Kusztal, Mariusz
Weyde, Waclaw
Klinger, Marian
POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2016, 70 : 654 - 667
[9] Maintenance treatment of ANCA-associated vasculitides
Guillevin, L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : S199 - S201
[10] Genetics of ANCA-associated Vasculitides
Ugarte-Gil, Manuel F.
Espinoza, Luis R.
CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (07)

← 1 2 3 4 5 →